HN2010001647A - INHIBIDORES DE HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA - Google Patents

INHIBIDORES DE HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA

Info

Publication number
HN2010001647A
HN2010001647A HN2010001647A HN2010001647A HN2010001647A HN 2010001647 A HN2010001647 A HN 2010001647A HN 2010001647 A HN2010001647 A HN 2010001647A HN 2010001647 A HN2010001647 A HN 2010001647A HN 2010001647 A HN2010001647 A HN 2010001647A
Authority
HN
Honduras
Prior art keywords
estearoil
heterociclic
desaturasa
coa
inhibitors
Prior art date
Application number
HN2010001647A
Other languages
English (en)
Inventor
Chowdhury Sultan
Dales Natalie
Fonarev Julia
Fu Jianmin
Hou Duanjie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2010001647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HN2010001647A publication Critical patent/HN2010001647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA DERIVADOS HETEROCICLICOS DE LA FORMULA (I) QUE MODULAN LA ACTIVIDAD DE LA ESTEAROIL-CoADESATURASA. TAMBIEN SE ABRACAN METODOS PARA UTILIZAR ESTOS DERIVADOS CON EL FIN DE MODULAR LA ACTIVIDAD DE ESTEAROIL-CoADESATURASA, Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN TALES DERIVADOS.
HN2010001647A 2008-02-20 2010-08-19 INHIBIDORES DE HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA HN2010001647A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20

Publications (1)

Publication Number Publication Date
HN2010001647A true HN2010001647A (es) 2013-11-11

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010001647A HN2010001647A (es) 2008-02-20 2010-08-19 INHIBIDORES DE HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA

Country Status (29)

Country Link
US (2) US8049016B2 (es)
EP (1) EP2245029B1 (es)
JP (2) JP5507474B2 (es)
KR (1) KR101584826B1 (es)
CN (1) CN102007123B (es)
AR (1) AR070429A1 (es)
AU (1) AU2009216769A1 (es)
BR (1) BRPI0907826A2 (es)
CA (1) CA2715947C (es)
CL (1) CL2009000381A1 (es)
CO (1) CO6290655A2 (es)
CR (1) CR11629A (es)
CU (1) CU23890B1 (es)
EA (1) EA022797B1 (es)
EC (1) ECSP10010411A (es)
HK (1) HK1144808A1 (es)
HN (1) HN2010001647A (es)
IL (1) IL207578A (es)
JO (1) JO3014B1 (es)
MA (1) MA32150B1 (es)
MX (1) MX2010009158A (es)
MY (1) MY156317A (es)
NZ (1) NZ587350A (es)
PE (1) PE20091473A1 (es)
SV (1) SV2010003650A (es)
TW (1) TWI457338B (es)
UA (1) UA105000C2 (es)
WO (1) WO2009103739A1 (es)
ZA (1) ZA201005725B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007351498B2 (en) 2006-08-15 2012-04-05 Xenon Pharmaceuticals Inc. Organic compounds
CN101595105B (zh) * 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
NZ587350A (en) 2008-02-20 2012-07-27 Novartis Ag Thiazole derivatives featuring an imidazolidine or triazole derivative as inhibitors of stearoyl-CoA desaturase
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
MX2012003938A (es) * 2009-10-01 2012-08-03 Xenon Pharmaceuticals Inc Derivados de pirazol que modulan la estearoil-coa-desaturasa.
KR20150007349A (ko) * 2012-05-11 2015-01-20 애브비 인코포레이티드 Nampt 억제제
BR112014028954A2 (pt) 2012-05-21 2017-07-18 Novartis Ag amidas de n-piridinila substituídas no anel como inibidores da quinase
EP3511332A4 (en) * 2016-09-08 2020-03-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE, PREPARATION PROCESS AND USE THEREOF
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
JP2020514293A (ja) 2017-01-06 2020-05-21 ユマニティ セラピューティクス，インコーポレーテッド 神経障害を治療する方法
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2021083182A1 (zh) * 2019-10-28 2021-05-06 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH590267A5 (es) * 1972-10-04 1977-07-29 Ciba Geigy Ag
US4058617A (en) * 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
US7495018B2 (en) 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
WO2002051442A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
WO2005077937A1 (en) 2004-01-09 2005-08-25 Cadila Healthcare Limited Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1807085B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083992A (zh) * 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
WO2007130075A1 (en) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007143597A2 (en) * 2006-06-05 2007-12-13 Novartis Ag Organic compounds
AU2007351498B2 (en) * 2006-08-15 2012-04-05 Xenon Pharmaceuticals Inc. Organic compounds
EP2086970B1 (en) * 2006-08-24 2014-02-26 Novartis AG 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
BRPI0718509A2 (pt) * 2006-09-22 2015-09-29 Novartis Ag compostos orgânicos heterocíclicos
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
CN101595105B (zh) * 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
CN101910169A (zh) * 2008-02-13 2010-12-08 卫材R&D管理有限公司 双环胺衍生物
NZ587350A (en) 2008-02-20 2012-07-27 Novartis Ag Thiazole derivatives featuring an imidazolidine or triazole derivative as inhibitors of stearoyl-CoA desaturase
EA201100049A1 (ru) 2008-06-27 2011-08-30 Новартис Аг Органические соединения

Also Published As

Publication number Publication date
AR070429A1 (es) 2010-04-07
CU20100170A7 (es) 2011-10-31
EA201001315A1 (ru) 2011-06-30
US20120014906A1 (en) 2012-01-19
US8049016B2 (en) 2011-11-01
CR11629A (es) 2010-11-16
CL2009000381A1 (es) 2010-09-10
CA2715947A1 (en) 2009-08-27
KR101584826B1 (ko) 2016-01-18
US8318949B2 (en) 2012-11-27
ZA201005725B (en) 2011-04-28
MA32150B1 (fr) 2011-03-01
IL207578A0 (en) 2010-12-30
PE20091473A1 (es) 2009-10-23
HK1144808A1 (en) 2011-03-11
CA2715947C (en) 2016-10-25
CU23890B1 (es) 2013-04-19
KR20100117677A (ko) 2010-11-03
EP2245029B1 (en) 2015-04-15
JP2014132025A (ja) 2014-07-17
JP5507474B2 (ja) 2014-05-28
EP2245029A1 (en) 2010-11-03
SV2010003650A (es) 2011-07-05
JP2011512384A (ja) 2011-04-21
JO3014B1 (ar) 2016-09-05
MY156317A (en) 2016-02-15
BRPI0907826A2 (pt) 2019-12-10
AU2009216769A1 (en) 2009-08-27
CN102007123B (zh) 2014-04-30
IL207578A (en) 2014-11-30
NZ587350A (en) 2012-07-27
CN102007123A (zh) 2011-04-06
WO2009103739A1 (en) 2009-08-27
JP5813162B2 (ja) 2015-11-17
CO6290655A2 (es) 2011-06-20
TWI457338B (zh) 2014-10-21
MX2010009158A (es) 2010-09-24
EA022797B1 (ru) 2016-03-31
ECSP10010411A (es) 2010-09-30
US20090264444A1 (en) 2009-10-22
TW200942534A (en) 2009-10-16
UA105000C2 (uk) 2014-04-10

Similar Documents

Publication Publication Date Title
HN2010001647A (es) INHIBIDORES DE HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
GT201000376A (es) Compuestos organicos
GT200900027A (es) Compuestos organicos
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CR20130267A (es) Inhibidores de nampt y rock
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
GT200600117A (es) Nuevos compuestos farmaceuticos
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
UY33735A (es) Compuestos antivirales
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
NO20090783L (no) Pyrimidonforbindelser som inhibitorer av GSK-3
BR112012000968A8 (pt) Composto, composição e método para inibir uma fosfatidil inositol-3 cinase.
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
UY32776A (es) Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
UY33539A (es) Compuestos químicos alk
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CO6321288A2 (es) Sales de compuestos inhibidores de vih
TN2009000510A1 (en) Extended release formulation of nevirapine
ECSP12012198A (es) Uso de nuevos inhibidores de pan-cdk para tratar tumores
PA8792401A1 (es) Fenilendiaminas
CR20120134A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa